AIM ImmunoTech (NYSE:AIM – Get Free Report) had its price target dropped by equities researchers at Maxim Group from $2.00 to $1.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 271.75% from the company’s previous close.
Separately, Ascendiant Capital Markets reduced their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.
Read Our Latest Research Report on AIM ImmunoTech
AIM ImmunoTech Stock Up 1.5 %
AIM ImmunoTech (NYSE:AIM – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. The business had revenue of $0.05 million for the quarter. As a group, equities analysts predict that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is currently owned by hedge funds and other institutional investors.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Featured Articles
- Five stocks we like better than AIM ImmunoTech
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Basic Materials Stocks Investing
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What is the Nikkei 225 index?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.